With strong government support over the past two decades, the Singaporean life sciences industry has matured. Initially known as a manufacturing hub, Singapore’s innovation ecosystem is now thriving, but the challenge is to cultivate commercialization power.

Emerging companies including Bliss Biopharmaceutical, Coherent Biopharma and WestGene Biopharma lifted China biotech funding from May to mid-June.

Cross-border deals are down and investment has dried up, while geopolitical tensions have started hitting the Chinese biotech sector in unprecedented ways. Biopharma firms are expecting more rainy days ahead and are embracing new fundraising and deal-making approaches to survive and thrive.

The Chinese biopharma industry is eager to use the latest artificial intelligence technology to boost efficiency and lighten workloads, as companies deal with drastic change and look to improve their understanding of foreign markets. Meanwhile, senior European leaders called for a level playing field during a recent visit to China.